



-PRESS RELEASE-

Ceruvia Founder and CEO, Carey Turnbull, to Appear at *Wonderland Miami*

Greenwich, Connecticut, October 27, 2022 – Ceruvia Lifesciences, a leading neurotransformational biopharmaceutical company, today announced that its Founder and CEO, Carey Turnbull, will appear at *Wonderland Miami* on Saturday, November 5th at 10:40am for a panel discussion on *The Importance of Bringing Psychedelic Psychiatry Into The Mainstream Of The Medical Establishment*. Turnbull will be joined on the panel by Yale Professors and Ceruvia OCD trial Principal Investigators, Dr. Christopher Pittenger and Dr. Ben Kelmendi, as well as by NYU Assistant Professor, Dr. Kelly O’Donnell, and Johns Hopkins Assistant Professor, Dr. Natalie Gukasyan.

“Given the many challenges we will face as we look to integrate psychedelic medicine into the medical system, I am looking forward to the opportunity to discuss this critical issue with this esteemed group of professionals”, said Carey Turnbull.

For further details or to register to attend, please visit: <https://microdose.buzz/wonderland>
Discounted tickets to attend virtually or in-person may be purchased using the code: CERUVIA20

About Ceruvia Lifesciences

Founded in 2017, Ceruvia Lifesciences is a clinical-stage biopharmaceutical company with a mission to improve the lives of underserved patients suffering from neurological and psychiatric disorders. Founded by Carey Turnbull, Ceruvia is relentlessly focused on the development and commercialization of neurotransformational medicines to deliver meaningful relief to patients suffering from hard-to-treat headache disorders, OCD and substance abuse disorder. For too long, these communities have been poorly understood and under-served. At Ceruvia, we believe they no longer have to live this way. With leading researchers at Yale University School of Medicine, NYU School of Medicine and Harvard Medical School, Ceruvia is undertaking clinical

research in order to help them return to living their lives to the fullest. For more information, please visit www.ceruvialifesciences.com

Media inquiries:

Contact: Christopher Koddermann

Tel.: +41 (79) 434 25 78

E-Mail: chris@nyprg.org